INBX250117C30000
- 4.20
- 0.000.00%
Inhibrx Biosciences Newsroom
Inhibrx Biosciences Analyst Ratings
Inhibrx Prospective Colorectal Cancer Treatment Shows Encouraging Results, Trial Expansion Planned
Inhibrx Biosciences Reports Promising Trial Results for INBRX-109
Express News | Inhibrx Biosciences Inc - Phase 1 Trial Shows 1 Complete Response, 3 Partial Responses, 6 Stable Disease Cases
Express News | Inhibrx Biosciences Announces Preliminary Data From the Phase 1 Trial of Ozekibart (Inbrx-109) for the Treatment of Colorectal Cancer
Inhibrx Biosciences Announces Preliminary Data From the Phase 1 Trial of Ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
Express News | Inhibrx Biosciences Announces Loan Agreement With Oxford Finance
Press Release: Inhibrx Biosciences Announces Loan Agreement With Oxford Finance
Inhibrx Biosciences Insider Bought Shares Worth $1,523,620, According to a Recent SEC Filing
JMP Securities Sticks to Their Hold Rating for Inhibrx Biosciences Inc (INBX)
The Recent Drop in Prices Must Have Disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) Institutional Investors Who Own 43% of the Shares
Inhibrx Biosciences | 10-Q: Quarterly report
Inhibrx Biosciences | 8-K: Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
Express News | Inhibrx Q3 Operating Income USD -46.797 Million
Inhibrx Biosciences 3Q Loss $43.9M >INBX
Inhibrx Biosciences 3Q Loss/Shr $2.84 >INBX
Inhibrx Biosciences 3Q Rev Negative $119,000 >INBX
Inhibrx: Jury Found in Favor of Inhibrx, Rejecting All Allegations of Misappropriation >INBX
Express News | Inhibrx Biosciences Inc: Legal Victory in a Trade Secrets Case Brought by I-Mab Biopharma
Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX)